Showing 1 - 20 results of 242 for search '(((( 50 ppm decrease ) OR ( 50 _ decrease ))) OR ( 19 p decrease ))', query time: 0.13s Refine Results
  1. 1

    Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…<p dir="ltr">Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex: Frontiers in Molecular Biosciences <a href="https://dx.doi.org/10.3389/fmolb.2022.846996" target="_blank">https://dx.doi.org/10.3389/fmolb.2022.846996</a>, published online 22 July 2022.…”
  2. 2

    Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…By elucidating a mechanistic basis for the increased affinity of the N501Y mutant S1-RBD for ACE2, we believe that the results presented here will aid in developing therapeutic strategies against SARS-CoV-2 including designing of therapeutic agents targeting the ACE2-S1-RBD interaction.</p><p dir="ltr">Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex: Frontiers in Molecular Biosciences: <a href="https://dx.doi.org/10.3389/fmolb.2022.1018464" rel="noreferrer" target="_blank">https://dx.doi.org/10.3389/fmolb.2022.1018464</a>, published online 19 October 2022.…”
  3. 3
  4. 4
  5. 5

    Ecotoxicological Assessment of Thermally- and Hydrogen-Reduced Graphene Oxide/TiO<sub>2</sub> Photocatalytic Nanocomposites Using the Zebrafish Embryo Model by Halema Al-Kandari (6316961)

    Published 2019
    “…For the RGOTi, the no observed effect concentration (NOEC, mortality/teratogenicity score <20%) and the median lethal concentration (LC<sub>50</sub>) were <400 and 748.6 mg/L, respectively. …”
  6. 6
  7. 7
  8. 8
  9. 9

    From COVID-19 to clot: the involvement of the complement system by Mohamed A. Hendaus (9401919)

    Published 2020
    “…<p dir="ltr">In December 2019, the world observed an unexpected outbreak of an emerging disease named coronavirus (COVID-19) that was first reported in Wuhan city of Hubei province of China. …”
  10. 10

    Effects of COVID-19 on Autism Spectrum Disorder in Qatar by Fouad A. Alshaban (17281108)

    Published 2024
    “…</p><h3>Methods</h3><p dir="ltr">This study used quantitative and qualitative survey data from parents in Qatar (n=271), to understand the impact of the COVID-19 pandemic on autistic children and their families in Qatar. …”
  11. 11

    COVID-19 biomarkers for severity mapped to polycystic ovary syndrome by Abu Saleh Md Moin (6189512)

    Published 2020
    “…<p dir="ltr">Large scale multi-omics analysis has identified significant differences in the biomarkers between COVID-19 disease and control subjects [1]. …”
  12. 12

    COVID-19 and Anemia: What Do We Know So Far? by Luai Abu-Ismail (10712857)

    Published 2023
    “…<p dir="ltr">On 11 March 2020, the World Health Organization (WHO) declared the novel SARS-CoV-2 virus responsible for causing COVID-19, a global pandemic. …”
  13. 13

    Ambulatory general urgent clinic: an initiative at the time of COVID-19 pandemic by Abdullah Al-Hothi (18505290)

    Published 2024
    “…Our quality improvement study aimed to decrease the waiting time by 20%, from 21 days in January 2021 to 14 days in April 2021, to evaluate the newly established clinics for urgent referrals during the COVID-19 pandemic, and to assess the physicians’ satisfaction regarding these clinics.…”
  14. 14

    The Impact of COVID-19 on the HIV Cascade of Care in Botswana – An Interrupted Time Series by Alice Sehurutshi (21842696)

    Published 2024
    “…In multivariable Poisson interrupted time series regression, the COVID-19 lockdown was associated with a 27% decrease in the monthly numbers of HIV tests (IRR 0.73, 95%CI 0.72–0.73), a 25% decrease in HIV positive tests (IRR 0.75, 95%CI 0.71–0.79), and a 43% reduction in ART initiations (IRR 0.57, 95%CI 0.55–0.60). …”
  15. 15

    Nebulized fentanyl for respiratory symptoms in patients with COVID-19 (ventanyl trial) by Nissar Shaikh (11659441)

    Published 2022
    “…<p dir="ltr">Patients with coronavirus disease (COVID-19) commonly experience distressing and challenging respiratory symptoms. …”
  16. 16

    Sleeping habits during COVID-19 induced confinement: A study from Jordan by Mahmoud A. Alomari (14780446)

    Published 2021
    “…Majority of the participants (53–59%) reported an increase in most of the sleep parameters except a decrease (49.1%) in daytime sleep. Age was associated with changes in sleeping disturbances during COVID-19 confinement (p < 0.001). …”
  17. 17

    Changes in Physical Activity and Sedentary Behavior Amid Confinement: The BKSQ-COVID-19 Project by Mahmoud A Alomari (12150939)

    Published 2020
    “…<h3>Background</h3><p dir="ltr">Coronavirus disease 19 (COVID-19) has compelled implementing confine ment measure across the globe. …”
  18. 18

    The impact of COVID‐19 pandemic lockdown on smoking habits and lifestyle: A cross‐sectional study by Almu'atasim Khamees (11875640)

    Published 2023
    “…<h3>Background and Aims</h3><p dir="ltr">Throughout the COVID‐19 lockdown, the resultant psychological disturbances led to more tobacco consumption and deteriorated smoking behaviors among smokers. …”
  19. 19

    The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review by Mahmoud Yousef (9900837)

    Published 2024
    “…<h3>Aims</h3><p dir="ltr">Emerging evidence highlights the role of COVID-19 in instigating gut dysbiosis, with repercussions on disease severity and bidirectional gut-organ communication involving the lung, heart, brain, and liver. …”
  20. 20

    Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity by Abu Saleh Md Moin (6189512)

    Published 2021
    “…It is unclear if these protein changes in T2D may predict worse COVID-19 disease for these patients.</p><h3>Clinical Trial Registration</h3><p dir="ltr">https://clinicaltrials.gov/, identifier NCT03102801.…”